Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.43 |
| ▸ | CES1 | P23141 | 6/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PKLR | P30613 | 1/20 | 0.30 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28558 | 0.79 | — | — | |
| SCHEMBL7705802 | 0.78 | CES2 (0.36) | CES2CES1BCHEHPGDALB | |
| SCHEMBL2052718 | 0.77 | CES2 (0.41) | CES2CES1BCHE | |
| SCHEMBL97028 | 0.76 | CYP3A4 (0.40) | CES2CES1BCHEHDAC4DAO | |
| SCHEMBL9671253 | 0.76 | CES2 (0.34) | CES2CES1BCHEDAO | |
| SCHEMBL1145126 | 0.76 | TSHR (0.38) | HPGDHDAC4 | |
| SCHEMBL2045858 | 0.76 | CES2 (0.34) | CES2CES1BCHE | |
| SCHEMBL2045854 | 0.76 | IDO1 (0.37) | LMNAPTGES2 | |
| SCHEMBL1004626 | 0.75 | CES2 (0.38) | CES2CES1BCHEBCAT1ALB | |
| SCHEMBL158537 | 0.75 | BCAT1 (0.49) | CES2CES1BCHEHPGDBCAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159542-A | Substituted 2, 3-dihydro [1,3] thiazolo [4,5-b ] pyridines, salts thereof and their use as herbicidal agents | 拜耳公司 | 2024-06-07 | — | — | CN | claimed |
| CN-114479064-B | Antibacterial polyaryletherketone night-grinding tooth jaw pad and preparation method thereof | 吉林省登泰克牙科材料有限公司 | 2024-01-02 | — | — | CN | claimed |
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2023-03-07 | — | — | US | claimed |
| CN-115611855-A | Nicotinamide type compound and application thereof in preparation of weight-losing medicine | 西北大学 | 2023-01-17 | — | — | CN | claimed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | claimed |
| CN-110156646-B | Method for synthesizing difluoroalkyl or difluoromethyl sulfur (selenium) -containing compound | 台州学院 | 2021-02-26 | — | — | CN | claimed |
| CN-109952301-A | 5-HT2C receptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2019-06-28 | — | — | CN | claimed |
| US-9938312-B2 | Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-04-10 | — | — | US | claimed |
| EP-3038621-A2 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | Human Biomolecular Research Institute (US) | 2016-07-06 | — | — | EP | claimed |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2016-02-11 | — | — | US | claimed |
| WO-2010117803-A2 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| EP-2089425-A2 | ANTI-ANGIOGENIC COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2009-08-19 | — | — | EP | claimed |
| EP-2001896-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | Agilent Technologies, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | claimed |
| WO-2008056346-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-05-15 | — | — | WO | claimed |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | claimed |
| EP-1851199-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2007112263-A2 | MONOMER COMPOSITIONS FOR THE SYNTHESIS OF RNA, METHODS OF SYNTHESIS, AND METHODS OF DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | WO | claimed |
| WO-2006086705-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | claimed |
| EP-0596917-B1 | BENZIMIDAZOLE ANTHELMINTICS | PFIZER LTD (GB) | 1998-10-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | CES2 4108/4885CES1 4462/4885BCHE 3781/4885 |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | HTR2A, HTR2B, HTR2C | CES2 405/4885CES1 1510/4885BCHE 1338/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | CES2 4310/4885CES1 3423/4885BCHE 4472/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | CES2 4108/4885CES1 4462/4885BCHE 3781/4885 |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | CES2 4063/4885CES1 4830/4885BCHE 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.